
CLAIMS

We claim:

1. A compound having a formula:



(1),

or a pharmaceutically acceptable salt thereof;

wherein

J^5 is H or $S(O)_2$-(C_{1-6} alkyl);

R^1 is H, CN, halogen, C_{1-6} alkyl, O-(C_{1-6} alkyl), or C_{3-7} cycloalkyl;

A is C_{6-16} aryl or C_{2-15} heterocyclyl, each of which may be substituted with 1 or 2 groups selected, independently, from OH, halogen, C_{1-6} alkyl, (C_{1-6} alkylene)-OH, O-(C_{1-6} alkyl), (C_{1-6} alkylene)-O-(C_{1-6} alkyl), $S(O)_2$-(C_{1-6} alkyl), C_{3-7} cycloalkyl, (C_{1-16} alkylene)-C(O)OH, (C_{1-16} alkylene)-C(O)N(H)-(C_{1-6} alkyl), (C_{1-16} alkylene)-C(O)N(H)-OH, or (C_{1-6} alkylene)-N(C_{1-6} alkyl)-(C_{1-6} alkyl);


J^3 is CN, OH, NH_2, C_{1-6} alkyl, C_{1-6} alkynyl, C_{3-7} cycloalkyl, (C_{1-3} alkylene)-CN, (C_{1-3} alkylene)-NH_2, (C_{1-3} alkylene)-N(H)C(O)-(C_{3-7} cycloalkyl), (C_{1-3} alkylene)-N(H)C(O)-(C_{2-8} heterocycloalkyl), O-(C_{3-7} cycloalkyl), O-(C_{1-3} alkylene)-CN, N(H)C(O)-(C_{3-7} cycloalkyl), N(H)C(O)-(C_{2-8} heterocycloalkyl), N(H)C(O)-(C_{2-5} heteroaryl), N(H)C(O)-(C_{1-3} alkylene)-(C_{2-5} heteroaryl), N(H)C(O)-(C_{6-10} aryl), N(H)C(O)-(C_{1-3} alkylene)-(C_{6-10} aryl), N(H)C(O)NH_2, N(H)(C_{1-6} alkyl), N(H)(C_{3-7} cycloalkyl), N(C_{1-6} alkyl)(C_{3-7} cycloalkyl), N(H)(C_{1-3} alkylene)-(C_{2-8} heterocycloalkyl), N(H)(C_{1-3} alkylene)-(C_{2-5} heteroaryl), N(H)(C_{1-3} alkylene)-(C_{6-10} aryl), or C_{2-15} heterocyclyl, each of which may be substituted with 1, 2, 3, or 4 groups selected, independently, from halogen, O, OH, O-(C_{1-6} alkyl), $S(O)_2$-(C_{1-6} alkyl), $S(O)_2$-(C_{1-6} haloalkyl), C(NH_2)(NH), C_{1-6} alkyl, C_{1-6} haloalkyl, (C_{1-6} alkylene)-OH, (C_{1-6} alkylene)-O-(C_{1-6} alkyl), (C_{1-6} alkylene)-O-(C_{1-6} haloalkyl), (C_{1-6} alkylene)-$S(O)_2$-(C_{1-6} alkyl), (C_{1-6} alkylene)-NH_2, (C_{1-6} alkylene)-N(H)(C_{1-6} alkyl), (C_{1-6} alkylene)-N(C_{1-6} alkyl)(C_{1-6} alkyl), (C_{1-6} alkylene)-(C_{3-7} cycloalkyl), (C_{1-6} alkylene)-(C_{3-7} halocycloalkyl), (C_{1-6} alkylene)-(C_{2-5} heteroaryl), (C_{1-6} alkylene)-(C_{6-10} haloaryl), NH_2, N(H)(C_{1-6} alkyl), N(C_{1-6} alkyl)(C_{1-6} alkyl), N(H)-(C_{1-3} alkylene)-(C_{3-7} cycloalkyl), N(C_{1-6} alkyl)-(C_{1-3} alkylene)-(C_{3-7} cycloalkyl), N(H)C(O)O-(C_{1-6} alkyl), N(H)$S(O)_2$-(C_{1-6} alkyl), C(O)-(C_{1-6} alkyl), C(O)-(C_{1-6} alkylene)-CN, C(O)-(C_{1-6} alkylene)-NH_2, C(O)-(C_{1-6} alkylene)-N(H)(C_{1-6} alkyl), C(O)-(C_{1-6} alkylene)-N(C_{1-6} alkyl)(C_{1-6}

alkyl), C(O)-(C_{1-6} alkylene)-N(H)[$S(O)_2$-C_{1-6} alkyl], C(O)-(C_{1-6} alkylene)-N(C_{1-6} alkyl)[$S(O)_2$-C_{1-6} alkyl], or C(O)O-(C_{1-6} alkyl); and

R^4 is H, OH, C_{1-6} alkyl, (C_{1-6} alkylene)-OH, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{3-7} halocycloalkyl, (C_{1-3} alkylene)-(C_{3-7} cycloalkyl), (C_{1-6} alkylene)CN, (C_{1-6} alkylene)-C(O)O-(C_{1-6} alkyl), (C_{1-6} alkylene)-OC(O)-(C_{1-6} alkyl), or C_{2-8} heterocycloalkyl;

or J^3 and R^4, together with the atoms to which they are attached, combine to form C_{3-7} cycloalkyl, C_{2-8} heterocycloalkyl, CC(H)-(C_{0-6} alkylene)CN, C_{3-7} cycloalkyl substituted with 1 or 2 groups selected, independently, from halogen or (C_{1-6} alkylene)CN, or C_{2-8} heterocycloalkyl substituted with 1 or 2 groups selected, independently, from halogen or (C_{1-6} alkylene)CN.

2. The compound of claim 1, having a formula:



(**I**)

or a pharmaceutically acceptable salt thereof,

wherein

R^1 is H, F, Cl, Br, I, CN, NH_2, OH, OCF_3, OCH_2CF_3, C_{1-6} alkyl, C_{3-6} cycloalkyl, or C_{1-6} haloalkyl,


R^2 and R^3 are C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^2 and R^3 combine to form a heteroalkyl or polycyclic ring of at least 4 member atoms and at most 12 member atoms,

R^4 is C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, -CH_2CN, -CH_2CH_2CN, -$CH_2CH_2CH_2CN$, alkylenecycloalkyl, alkylenecyclopropyl, or hydroxyl, and

A is phenyl, or a monocyclic C_{3-5} heteroaryl having 1–3 heteroatoms, wherein each heteroatom is, independently, N, O, or S.

3. The compound of claim 2, wherein A is a monocyclic C_{3-5} heteroaryl having 1–3 heteroatoms, wherein each heteroatom is, independently, N, O, or S.

4. The compound of claim 2 or 3, wherein the compound is of the formula:



(**II**)


or a pharmaceutically acceptable salt thereof,

wherein

R^2 and R^3 are C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^2 and R^3 combine to form a heteroalkyl or polycyclic ring of at least 4 member atoms and at most 10 member atoms, and

R^5 is C_{1-12} alkyl, C_{1-12} heteroalkyl or C_{1-12} haloalkyl, CH_2OH, CH_2CH_2OH, $CH_2CH_2CH_2OH$, alkylenecycloalkyl, alkylenecyclopropyl, or methoxy.

5. The compound of claim 3, wherein the compound is of the formula:



(**III**)

or a pharmaceutically acceptable salt thereof,

wherein


R^2 and R^3 are C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^2 and R^3 combine to form a heteroalkyl or polycyclic ring of at least 4 member atoms and at most 8 member atoms,

R^6 is C_{1-12} alkyl, C_{1-12} heteroalkyl or C_{1-12} haloalkyl, $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$, $-(CH_2)_n-COOR^{10}$, alkylenecycloalkyl, alkylenecyclopropyl, or methoxy,

n is an integer between one and ten, and

R^{10} is hydrogen, alkyl, cycloalkyl, heteroalkyl.

6. The compound of claim 2, wherein the compound is of the formula:



(**IV**)

or a pharmaceutically acceptable salt thereof,


wherein

R^2 and R^3 are C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^2 and R^3 combine to form a heteroalkyl ring of at least 4 member atoms and at most 8 member atoms,

X is CH or N, and

R^7 and R^8 are independently H, C_{1-12} alkyl, C_{1-12} heteroalkyl, or C_{1-12} haloalkyl, CH_2OH, CH_2CH_2OH, $CH_2CH_2CH_2OH$, alkylenecycloalkyl, alkylenecyclopropyl, or methoxy, or R^7 and R^8 combine to form a heteroalkyl ring of at least 4 member atoms and at most 8 member atoms.

7. The compound of claim 4, wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof,


wherein

R^1 is H, Cl, C_{1-6} alkyl, C_{3-6} cycloalkyl, or C_{1-3} haloalkyl,

R^2 and R^3 are C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^2 and R^3 combine to form a heteroalkyl ring of at least 4 member atoms and at most 8 member atoms, and

R^5 is C_{1-6} alkyl, C_{3-5} cycloalkyl, CH_2OH, CH_2CH_2OH, $CH_2CH_2CH_2OH$, alkylenecycloalkyl, alkylenecyclopropyl, or methoxy.

8. The compound of claim 5, wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof,

wherein

R^1 is H, F, Cl, OCF_3, OCH_2CF_3, C_{1-6} alkyl, C_{3-6} cycloalkyl, or C_{1-6} haloalkyl,






R^2 and R^3 are C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^2 and R^3 combine to form a heteroalkyl ring of at least 4 member atoms and at most 8 member atoms,













R^6 is C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$, $-(CH_2)_n-COOR^{10}$, alkylenecyclopropyl, or methoxy,














n is an integer between one and ten, and













R^{10} is hydrogen, alkyl, cycloalkyl, heteroalkyl.













9. The compound of claim 1, which is selected from:


















,

,

,

,

,


















,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,




















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, having the formula:



(**V**)

or a pharmaceutically acceptable salt thereof,


R^1 is H, F, Cl, Br, I, CN, OCF_3, OCH_2CF_3, C_{1-3} alkyl, C_{3-6} cycloalkyl, or C_{1-6} haloalkyl,



R^4 is C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, CH_2CN, CH_2CH_2CN, $CH_2CH_2CH_2CN$, alkylenecycloalkyl, alkylenecyclopropyl, or hydroxyl,

R^9 is C_{1-6} alkyl, C_{1-6} heteroalkyl or C_{1-6} haloalkyl, or R^4 and R^9 combine to form a carbocyclic, polycyclic, or heteroalkyl ring of at least 4 member atoms and at most 8 member atoms, and

A is phenyl, or a monocyclic C_{3-5} heteroaryl having 1–3 heteroatoms, wherein each heteroatom is, independently, N, O, or S.


11. The compound of claim 1, which is selected from:



or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, having a formula:




or a pharmaceutically acceptable salt thereof;


wherein

J^5 is H, $S(O)_2CH_3$, or $S(O)_2CH_2CH_3$;


R^1 is H, CH_3, CH_2CH_3, cyclopropyl, OCH_3, F, Cl, or CN;


A is








J^3 is CN, OH, NH_2,















; and


R^4 is H, CH_3, CH_2CH_3, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, OH, CH_2OH, CH_2CH_2OH, CH_2F, CH_2CHF_2, CH_2CH_2F, CH_2CH_2Cl, CH_2-cyclopropyl, CH_2CN, CH_2CH_2CN, 3-fluorocyclobut-1-yl, tetrahydro-2H-pyran-4-yl, $CH_2C(O)OCH_3$, or $CH_2OC(O)CH_3$;

or J^3 and R^4, together with the atoms to which they are attached, combine to form




.


13. The compound of claim 1, which is selected from:




,




,



,





or a pharmaceutically acceptable salt thereof.

14. A composition, comprising the compound of any of claims 1–13.

15. A composition of claim 14, wherein the composition is a pharmaceutical composition.

16. A composition of claim 15, wherein the composition further includes a pharmaceutically acceptable carrier.

17. Use of the compound of any of claims 1–13, or the composition of any of claims 14–16, in the manufacture of a medicament for the treatment of an ocular disease or condition in a subject in need thereof.

18. Use of claim 17, wherein the ocular disease or condition is non-infectious uveitis, chorioretinitis, iritis, sterile conjunctivitis, keratitis, episcleritis, dry eye disease, meibomian

gland dysfunction, allergic conjunctivitis, injury-related ocular inflammation or dry eye syndrome, Primary Sjögren's syndrome, Secondary Sjögren's syndrome, redness, blepharitis, keratoconjunctivitis sicca, ocular hyperemia, Thygeson superficial punctate keratitis, or a combination of thereof.

19. Use of claim 17, wherein the ocular disease or condition is wet macular degeneration, dry macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, posterior uveitis, retinal inflammation, inflammation due to gene therapy vectors (*e.g.* viral vectors), graft versus host disease, blepharitis, or a combination thereof.

20. Use of the compound of any of claims 1–13, or the composition of any of claims 14–16, in the manufacture of a medicament for treating or reducing ocular inflammation in a subject in need thereof.

21. Use of the compound of any of claims 1–13, or the composition of any of claims 14–16, in the manufacture of a medicament for the treatment of an autoimmune disease or condition in a subject in need thereof.

22. Use of claim 21, wherein the autoimmune disease or condition is alopecia areata, alopecia universalis, polycythemia vera, vitiligo, multiple sclerosis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type I diabetes, lupus, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, autoimmune thyroid conditions, chronic obstructive pulmonary disease, organ transplantation, or a combination thereof.

23. Use of the compound of any of claims 1–13, or the composition of any of claims 14–16, in the manufacture of a medicament for the treatment of a disease or condition associated with kinase activity, or diseases or conditions affected by kinases, in a subject in need thereof.

24. Use of claim 23, wherein the disease or condition is a neurodegenerative disease or condition, an ocular disease or condition, a cardiovascular disease or condition, a cancer, a hematological cancer, a myeloproliferative condition, acute myeloid leukemia, lymphoma, or a combination thereof.

25. Use of any of claims 17–20, wherein the medicament is to be administered topically to an eye of the subject or topically to the eyelid of the subject.

26. Use of any of claims 17–20, wherein the medicament is to be administered by intravitreal injection into an eye of the subject.

27. The compound of any of claims 1–13, or the composition of any of claims 14–16, for use in therapy.

28. A kit, including a compound of any of claims 1–13, or a composition of any of claims 14–16, and instructions for use.